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Poster Session II 133Conditioning regimen was myeloablative for 92% of patients. It in-
cluded TBI in 39%, and ATG in 55%. GVHD prophylaxis was ta-
crolimus-based (except for 2 patients) with methotrexate (75%) or
MMF (19%). 44 patients (39%) received double CB units and 70
(61%) single units. Units were ex-vivo expanded for 20/44 and 9/
70 patients, respectively. Median number of infused total nucleated
cells (TNC) was 3.5 107/kg (1–7) and 4.7 107/kg (0.6–56) in the
adult and pediatric groups, respectively. cGVHD was defined ac-
cording to the recent NIH consensus criteria. Risk factors were
evaluated by Cox’s regression analysis including age, gender, disease
status at transplantation, a prior autologous transplant, condition-
ing regimen, use of ATG in conditioning, GVHD prophylaxis,
number of CB units received, number of infused TNC, HLA-A,
B, or DRB1 mismatch, and early withdrawal of immunosuppres-
sion.Results:With a median follow up of 9 months, 21/114 patients
developed cGVHD at a median of 126 days post CBT (range 100–
276). 62% of these cases (n 5 13) were de Novo. Recipient age
was the strongest risk factor with a significantly higher 1-year cumu-
lative incidence in adult patients (31%) compared with pediatric pa-
tients (n 5 4, 8%), p 5 0.002), despite a comparable incidence of
grade II-IV (38% and 34%) and III-IV (14% and 10%) acute
GVHD; and a superior disease free survival in the pediatric group.
In adult patients, a prior autologous transplant (n 5 16) was the
only significant risk factor, and was associated with a higher inci-
dence (50% versus 23%, p50.02). cGVHD was extensive in the ma-
jority of adult cases (12/17), yet it was associated with a lower rate of
relapse (HR 5 0.1, p 5 0.07) and mortality (HR 5 0.4, p 5 0.06)
when evaluated as time dependent variable in a landmark analysis
starting on post SCT day1100.Conclusions:Recipient age is a sig-
nificant predictor of cGVHD following CBT. In adult patients, the
impact of prior autologous transplant deserves further evaluation.363
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Severe acute graft-versus-host disease (GVHD) is a significant
cause of transplant related mortality in patients that receive alloge-
neic hematopoietic stem cell transplantation (HSCT). Treatment
of grade III and IV GVHD is frequently ineffective. Preemptive
treatment based on the early detection of cytokines associated
with T-cell activation and subclinical GVHD might be a more ef-
fective strategy, similar to the monitoring of CMV infection after
HSCT.
Various plasma markers of T cell activation, soluble IL-2 recep-
tor (sIL-2R) in particular, have been shown to correlate with cellular
immune responses in several diseases, including GVHD. Building
on this work, as the first step toward developing an early treatment
approach for severe GVHD, we conducted a prospective, observa-
tional study evaluating three plasma markers of T-cell activation.
sIL-2R, sCD40L and sCD8 were evaluated as screening tests with
the goal of detecting GVHD in its incipient stages prior to clinical
manifestations.
We measured plasma levels of these markers on days 5 and 10 fol-
lowing HSCT. Testing was performed in 50 transplants (49 pa-
tients). The median age of patients was 14 (range: 0–67); 19
received genotypically matched related transplants, 4 received mis-
matched related transplants, 20 received unrelated transplants, and
7 received unrelated cord blood transplants. This population in-
cluded patients with both malignant and non-malignant diseases
and who received myeloablative and reduced intensity conditioning
regimens. Nine patients developed grade III or IV GVHD. Re-
ceiver operating curves were generated for each of the markers at
both time points. This analysis showed sIL-2R and sCD8 to be
more accurate markers than sCD40L. Day 10 levels correlated
more closely with outcome than those measured on day 5. A parallel
testing strategy combining sIL-2R and sCD8 yielded results supe-
rior to using either marker alone.An elevation of sIL2r above 20 ng/mL or sCD8 above 4400 units/
mL on day 10 was seen in 8 out of 9 patients that developed grade III
or IV GVHD yielding a sensitivity of 0.89. For the specificity calcu-
lation, patients with grade II GVHD were considered to be cases,
since these patients routinely receive systemic treatment. This
method produced a specificity of 0.57.
The results of this pilot study demonstrate the feasibility of using
biomarkers of T-cell activation for the early detection of severe
acute GVHD. Plans are underway for a larger, more definitive ob-
servational study.364
THE RELATIONSHIP BETWEEN TACROLIMUS SERUM CONCENTRATIONS
AND ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC STEM CELL
RECIPIENTS
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Tacrolimus is commonly used as prophylaxis of GVHD follow-
ing allogeneic HSCT. While there is an association between in-
creasing serum tacrolimus levels and the incidence of renal
toxicity, there is no established relationship between tacrolimus
levels and the incidence of GVHD. We studied the outcome of
92 consecutive allogeneic blood HSCT recipients receiving tacroli-
mus-based GVHD prophylaxis. 55 had received conventional-in-
tensity conditioning (usually busulfan-fludarabine; 34 unrelated
donors and 21 sibling donors) where tacrolimus was combined
with short-course methotrexate, and 36 had received reduced-in-
tensity conditioning (melphalan6 cyclophosphamide; all unrelated
donors) where tacrolimus was combined with mycophenolate mofe-
til. For each patient, a weekly average tacrolimus level was deter-
mined for each of the first 7 weeks post-transplant by averaging
all the levels available for that week. The relationship between the
average weekly tacrolimus levels and the occurrence of any grade
of acute GVHD was examined. The ANOVA test was used to com-
pare the weekly average tacrolimus levels between patients who de-
veloped GVHD and those who did not. The cumulative incidence
of acute GVHD was compared by tacrolimus level categories each
week. A total of 1385 tacrolimus levels were available (6–45 per pa-
tient; median 14). The cumulative incidence of acute GVHD at 60
days was 37% (95% CI: 29–49%). As the table below shows, the av-
erage tacrolimus levels amongst patients going on to develop acute
GVHD tended to be lower than those not developing acute GVHD;
significantly so for week 4 and showing a trend towards significnace
for weeks 5 and 6. The cumulative incidence of acute GVHD
amongst patients whose week 3 average tacrolimus was\10 was
51% (95% CI: 39–68%) compared with 24% (95% CI: 14–41%)
for those with a level of$10 (P5 0.015). Similarly, the cumulative
incidence of acute GVHD amongst patients whose week 4 average
tacrolimus was\10 was 43% (95% CI: 32–59%) compared with
20% (95% CI: 10–41%) for those with a level of $10 (P 5
0.046). The relationship between higher acute GVHD incidence
and lower tacrolimus levels was observed for other weeks and tacro-
limus cut-off levels, but the differences were not statistically signif-
icant. Our data suggest that there is a relationship between
tacrolimus levels and acute GVHD. How this affects relapse rates,
transplant-related mortality, and survival remains to be determined.Median average tacrolimus levels in patients with or without acute
GVHD
Week Acute GVHD No acute GVHD P1 13.6 13.1 0.97
2 11.1 12.1 0.21
3 8.9 10.9 0.20
4 7.3 8.5 0.031
5 8.6 10.2 0.057
6 7.8 9.1 0.06
7 7.5 8.1 0.25
